Two-Mode Imaging System More Efficient for Tumor ID
Using NIR fluorescence with visible light reflectance imaging can help surgeons pinpoint the exact location of tumors, making removal easier and safer.
Using NIR fluorescence with visible light reflectance imaging can help surgeons pinpoint the exact location of tumors, making removal easier and safer.
Before they excise a tumor, surgeons need to determine exactly where the cancerous cells lie. Recognizing this, a team of researchers at the University of Arizona (Tucson, AZ) and Washington University in St. Louis (Missouri) has developed a multimodal imager that combines two systems—near-infrared (NIR) fluorescent imaging to detect marked cancer cells and visible light reflectance imaging to see the contours of the tissue itself—into a small, lightweight package that measures 25 mm across. The imager could lead to cheaper and more lightweight tools for surgeons, such as goggles or hand-held devices, to identify tumors in real time in the operating room.
Before they excise a tumor, surgeons need to determine exactly where the cancerous cells lie. Now, research published today in The Optical Society’s (OSA) journal Optics Letters details a new technique that could give surgeons cheaper and more lightweight tools, such as goggles or hand-held devices, to identify tumors in real time in the operating room.
Smaller, cheaper two-mode imaging system could help surgeons see and remove cancer
A team of scientists at Washington University School of Medicine in St. Louis (WUSTL) and the University of Arizona (UA) in Tucson led by Samuel Achilefu have created a pair of high-tech glasses that help surgeons visualize cancer cells during surgeries, which glow blue when viewed through the glasses
Wearable technology allows surgeons to see targeted molecular agent injected into patient that attaches to cancer cells, making them glow.
High-tech glasses may help surgeons visualize cancer cells, which glow blue when viewed through the eyewear. The wearable technology, so new it’s yet unnamed, was used during surgery for the first time today at Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.